JP2023523622A5 - - Google Patents

Info

Publication number
JP2023523622A5
JP2023523622A5 JP2022565707A JP2022565707A JP2023523622A5 JP 2023523622 A5 JP2023523622 A5 JP 2023523622A5 JP 2022565707 A JP2022565707 A JP 2022565707A JP 2022565707 A JP2022565707 A JP 2022565707A JP 2023523622 A5 JP2023523622 A5 JP 2023523622A5
Authority
JP
Japan
Prior art keywords
optionally
nucleic acid
transposase
approximately
myotis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022565707A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523622A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/030007 external-priority patent/WO2021222654A1/en
Publication of JP2023523622A publication Critical patent/JP2023523622A/ja
Publication of JP2023523622A5 publication Critical patent/JP2023523622A5/ja
Priority to JP2026064617A priority Critical patent/JP2026099993A/ja
Pending legal-status Critical Current

Links

JP2022565707A 2020-04-29 2021-04-29 遺伝性黄斑変性症の治療のための組成物及び方法 Pending JP2023523622A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026064617A JP2026099993A (ja) 2020-04-29 2026-04-09 遺伝性黄斑変性症の治療のための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063017442P 2020-04-29 2020-04-29
US63/017,442 2020-04-29
PCT/US2021/030007 WO2021222654A1 (en) 2020-04-29 2021-04-29 Compositions and methods for treatment of inherited macular degeneration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026064617A Division JP2026099993A (ja) 2020-04-29 2026-04-09 遺伝性黄斑変性症の治療のための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2023523622A JP2023523622A (ja) 2023-06-06
JP2023523622A5 true JP2023523622A5 (cg-RX-API-DMAC7.html) 2024-05-15

Family

ID=78332210

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022565707A Pending JP2023523622A (ja) 2020-04-29 2021-04-29 遺伝性黄斑変性症の治療のための組成物及び方法
JP2026064617A Pending JP2026099993A (ja) 2020-04-29 2026-04-09 遺伝性黄斑変性症の治療のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026064617A Pending JP2026099993A (ja) 2020-04-29 2026-04-09 遺伝性黄斑変性症の治療のための組成物及び方法

Country Status (9)

Country Link
US (1) US20230193319A1 (cg-RX-API-DMAC7.html)
EP (1) EP4142796A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023523622A (cg-RX-API-DMAC7.html)
KR (1) KR20230004573A (cg-RX-API-DMAC7.html)
CN (1) CN115461082A (cg-RX-API-DMAC7.html)
AU (1) AU2021265838A1 (cg-RX-API-DMAC7.html)
CA (1) CA3175197A1 (cg-RX-API-DMAC7.html)
IL (1) IL297718A (cg-RX-API-DMAC7.html)
WO (1) WO2021222654A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4146798A4 (en) 2020-05-04 2025-02-12 Saliogen Therapeutics, Inc. TRANSPOSITION-BASED THERAPIES
WO2023160454A1 (zh) * 2022-02-25 2023-08-31 北京中因科技有限公司 表达盒组合及其应用
EP4511496A4 (en) * 2022-04-18 2026-06-24 Abeona Therapeutics Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF DOMINANT OPTIC ATROPHY AND X-RELATED RETINOSCHISISIS
CN120936710A (zh) * 2023-02-02 2025-11-11 莱奥真生物科技有限公司 转座子系统的高活性转座酶蛋白及其用途
KR102839746B1 (ko) * 2023-04-27 2025-07-30 한국생명공학연구원 유전자의 망막 세포 내 발현을 위한 프로모터 및 이를 포함하는 벡터 시스템
CN120230798A (zh) * 2023-12-29 2025-07-01 上海朗昇生物科技有限公司 用于视网膜基因递送的重组腺相关病毒载体及其应用
WO2025147466A1 (en) * 2024-01-02 2025-07-10 Alkeus Pharmaceuticals, Inc. Treatment for asymptomatic stargardt disease patients
WO2025188836A1 (en) * 2024-03-05 2025-09-12 Saliogen Therapeutics, Inc. Compositions and methods of using gene coding for treating ocular disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309487B2 (en) * 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
US7943374B2 (en) * 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
KR20100097098A (ko) * 2007-09-27 2010-09-02 리비젼 쎄러퓨틱스, 인크. 레티놀 관련 질환을 치료하기 위한 방법 및 화합물
US20090214478A1 (en) * 2008-02-21 2009-08-27 Alberto Auricchio Method of treating ocular diseases by gene therapy
US20110311506A1 (en) * 2009-02-25 2011-12-22 The Johns Hopkins University Piggybac transposon variants and methods of use
WO2013173637A1 (en) * 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
DK2986635T3 (en) * 2013-04-18 2019-01-28 Fond Telethon EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
WO2015139093A1 (en) * 2014-03-21 2015-09-24 The Sydney Children's Hospitals Network (Randwick And Westmead) (Incorporating The Royal Alexandra Hospital For Children) Stable gene transfer to proliferating cells
JP7036723B2 (ja) * 2015-12-14 2022-03-15 コールド スプリング ハーバー ラボラトリー 眼疾患の処置のための組成物および方法
KR20200057051A (ko) * 2017-09-27 2020-05-25 시질론 테라퓨틱스, 인크. 활성 세포를 포함하는 방법, 조성물 및 이식 가능한 요소
WO2020077360A1 (en) * 2018-10-12 2020-04-16 Poseida Therapeutics, Inc. Hematopoietic stem cell compositions, methods of making and method of use

Similar Documents

Publication Publication Date Title
US20220387560A1 (en) Adeno-Associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease
US20230039928A1 (en) Antisense oligonucleotides for nucleotide deamination in the treatment of Stargardt disease
CA2904164C (en) Mir-204 and mir-211 and uses thereof
CN114829598A (zh) 一种治疗Usher综合征的方法和其组合物
JP2022546597A (ja) 閉端dnaおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法
AU2020260154B2 (en) Triple helix terminator for efficient RNA trans-splicing
JP2002534353A (ja) 高脂血症の遺伝子治療のための方法および化合物
CN108350446A (zh) 基于crispr/cas9的治疗
JP2022521764A (ja) Rho関連常染色体優性網膜色素変性症(adrp)を治療するためのcrispr/rna誘導ヌクレアーゼ関連の方法及び組成物
JP2023523622A (ja) 遺伝性黄斑変性症の治療のための組成物及び方法
JP2025534371A (ja) Opa1遺伝子変異に関連付けられる疾患を治療するためのopa1プレメッセンジャーrnaのトランススプライシングによる療法
JP2004532844A (ja) イオントホレシスのステップを含む方法により送達されるキメラオリゴヌクレオチドでの遺伝子療法
JP7334346B2 (ja) ロドプシン転写体に特異的なトランススプライシングリボザイム及びその用途
JP2025020293A (ja) アンチセンスオリゴヌクレオチドは、abca4の異常スプライシングをレスキューする
US20220305142A1 (en) Ocular delivery of therapeutic agents
CN116334141A (zh) 基于基因编辑的RHO-R135W-adRP基因编辑药物
US20260007773A1 (en) Ocular vectors and uses thereof
CN120641085A (zh) 包含核酸、可电离脂质、固醇、脂质锚定聚合物和辅助脂质的脂质纳米颗粒、其用途
RU2810907C1 (ru) Система направленного изменения сплайсинга в гене MARK2
US20260137813A1 (en) Genome editing methods and constructs
JP2026516065A (ja) シュタルガルト病を処置するためのデュアルaavベクター
EP4619525A1 (en) Methods for treating cep290 associated disease
WO2024110770A1 (en) A new promoter for retinal pigment epithelium (rpe) targeted gene therapy
WO2026039524A1 (en) Msh3 modulatory molecules
Cardoso et al. Nonviral Therapeutic Approaches for Modulation of Gene Expression: Nanotechnological Strategies to Overcome Biological Challenges